Indinol Forto - instructions for use, dose, side effects, contraindications

Active substanceIndolcarbinolIndolcarbinol

Similar drugsTo uncover

Indinol® Forto

capsules inwards

MiraxBioPharma, ZAO Russia

Indoprolone®

capsules inwards

MiraxBioPharma, ZAO Russia

Dosage form: & nbspcapsules

Composition:

1 capsule contains active substance: indolcarbinol (intrinol) -0.200 g;

Excipients: lactose monohydrate (sugar milk) - 0.110 g, corn modified corn starch -0.095 g, microcrystalline cellulose -0.064 g, sodium starch glycolate - 0.030 g, magnesium stearate-0.001 g,

gelatine capsule (capsules body: gelatin - up to 100%, purified water - 14-15%, titanium dioxide E 171 - 2.1128%, capsules gelatin capsule - up to 100%, purified water - 14-15%, titanium dioxide E 171 - 2 , 4375%, dye sunset sunset yellow E 110 - 0.108%).

Description:

Capsules hard gelatinous № 0 with the case of white color and a cover of orange color.

The contents of the capsule are powder from white to light yellow or light brown, with a weak specific odor.

Pharmacotherapeutic group:Mastodinia remedy - estrogen receptor modulator

ATX: & nbsp

G.03.X.C Selective modulators of estrogen receptors

Pharmacodynamics:

Indinol® Forto is a universal corrector of pathological hyperplastic processes in the tissues of the breast. The therapeutic effect of Indinol® Forto is based on its antiestrogenic and antiproliferative action.The main property of Indinol® Forto is its ability to cause selective death of breast cells with abnormally high proliferative activity. Indolcarbinol, enteringniin the composition of Indanol® Forto, modulates the cytochrome system in such a way that the resulting isoform of cytochrome P450 - CYP1A1 hydroxylates estrogens in the 2-nd position, with the formation of 2-hydroxyestrone (2-ONE1). The resulting metabolite is an antagonist of the estrogen receptor and blocks its activation by estrogen itself, as well as their dangerous metabolites, in particular 16-alpha hydroxyestrone (16α-ONE1), the proportion of which among metabolites is reduced. So the induction of estrogen-dependent genes is suppressed, and the cell ceases to receive excessive estrogen-dependent stimulation. The drug also blocks other signaling mechanisms (cytokines) that stimulate pathological cell growth in the mammary gland tissues, by suppressing the signal cascades from the corresponding receptors.

Course use of the drug helps to reduce the intensity and disappearance of pain in the mammary gland during cyclic mastalgia (mastodynia).

The use of the drug Indinol® Forto does not lead to an increase in body weight.

Indinol® Forto refers to practically non-toxic preparations (LD₅₀>5 g / kg).

Indications:

Cyclic mastalgia, including against the background of benign breast hyperplasia.

Contraindications:

The drug should not be used in the presence of any of the following conditions:

- hypersensitivity to the components of the drug;

- hereditary intolerance to galactose, deficiency of lactase or glucose-galactose malabsorption;

- the period of pregnancy and breastfeeding;

- Children under 18 years.

Pregnancy and lactation:

Contraindicated use of the drug Indinol® Forto during pregnancy and breastfeeding.

Dosing and Administration:

Inside, 2 times a day for 200 mg. The daily dose of the drug is 400 mg. Capsules are taken before meals. Duration of treatment 6 months.

Side effects:

On the part of the reproductive system: disorders of the menstrual cycle in the form of lengthening or shortening.

On the part of the digestive system: pain in epigastrium.

Laboratory indicators: increased concentration of thyrotropic and follicle-stimulating hormones, prolactin and estradiol, a decrease in creatinine concentration, eosinophilia.

Other: decrease in body weight.

Overdose:

Possible symptoms of an overdose include nausea, vomiting, diarrhea. The specific antidote is unknown. If you suspect an overdose of Indinol® Forto, symptomatic therapy is recommended.

Interaction:

Indolucarbinol affects the activity of cytochrome P450 isoenzymes, so caution should be exercised when combined with medicaments with cytochrome P450 isoenzymes involved in the metabolism (indirect anticoagulants, glucocorticosteroids, oral hypoglycemic agents, antiarrhythmic, antiepileptic, digitalis preparations, sex hormone preparations), since may need to adjust their dose.

Effect on the ability to drive transp. cf. and fur:

Based on the characteristics of pharmacodynamics and the profile of undesirable effects, it is unlikely that Indinol® Forto influences the ability to drive vehicles and work with machinery.

Form release / dosage:

Capsules, 200 mg.

Packaging:

For 20 capsules in a contour mesh box made of polyvinylchloride film and aluminum foil printed lacquered.

For 60, 90 or 120 capsules in cans of polymeric, sealed with a stretched plastic lid with a control of the first opening or in cans of polymeric for packing medicines. 3 or 6 contour packs of 20 capsules, or each jar, together with the instructions for use, are placed in a pack of cardboard.

Storage conditions:

In a dry, protected from light place at a temperature of no higher than 25 ° C.

Keep out of the reach of children.

Shelf life:

2 years.

Do not use after the expiration date printed on the package.

Terms of leave from pharmacies:On prescription

Registration number:LP-002010

Date of registration:20.02.2013 / 08.06.2017

Expiration Date:20.02.2018

Date of cancellation:2018-02-20

The owner of the registration certificate:MiraxBioPharma, ZAO MiraxBioPharma, ZAO Russia

Manufacturer: & nbsp

MiraxBioPharma, ZAO Russia

Information update date: & nbsp31.10.2017

Illustrated instructions

Instructions

Indinol® Forto (Indinol® Forto)